6575 Stock Overview
SyneuRx International (Taiwan) Corp., a clinical-stage biotech company, develops drugs for the treatment of unmet medical needs in central nervous system disorders in Taiwan.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
SyneuRx International (Taiwan) Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$17.20 |
| 52 Week High | NT$90.00 |
| 52 Week Low | NT$8.36 |
| Beta | 0.88 |
| 1 Month Change | 0% |
| 3 Month Change | -40.28% |
| 1 Year Change | -69.56% |
| 3 Year Change | -63.40% |
| 5 Year Change | -65.60% |
| Change since IPO | -93.41% |
Recent News & Updates
Shareholder Returns
| 6575 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | 0% | -5.4% | -2.1% |
| 1Y | -69.6% | 3.0% | 27.5% |
Return vs Industry: 6575 underperformed the TW Pharmaceuticals industry which returned 4.4% over the past year.
Return vs Market: 6575 underperformed the TW Market which returned 20.3% over the past year.
Price Volatility
| 6575 volatility | |
|---|---|
| 6575 Average Weekly Movement | 25.8% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in TW Market | 8.3% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6575's share price has been volatile over the past 3 months.
Volatility Over Time: 6575's weekly volatility has increased from 14% to 26% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | n/a | Guochuan Emil Tsai | www.syneurx.com |
SyneuRx International (Taiwan) Corp., a clinical-stage biotech company, develops drugs for the treatment of unmet medical needs in central nervous system disorders in Taiwan. Its pipeline includes Pentarlandir, which is in Phase II clinical trials for COVID-19; Airnecflu that is in Phase I clinical trials for COVID-19; NaBen, which is in Phase III clinical trials for adult schizophrenia, as well as in Phase II clinical trials adolescent schizophrenia; ClozaBen that is in Phase II clinical trials for refractory schizophrenia; NaBen, which is in Phase II clinical trials for early dementia; Tannquilynne that is in Phase II clinical trials for dementia and psychosis; Synapsinae, which is in Phase II clinical trials for early dementia and psychosis; and Synxyrin that is in Phase II clinical trials for early TRD and suicidality. SyneuRx International (Taiwan) Corp. was founded in 2013 and is based in New Taipei City, Taiwan.
SyneuRx International (Taiwan) Corp. Fundamentals Summary
| 6575 fundamental statistics | |
|---|---|
| Market cap | NT$2.08b |
| Earnings (TTM) | -NT$328.75m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.3x
P/E RatioIs 6575 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6575 income statement (TTM) | |
|---|---|
| Revenue | NT$0 |
| Cost of Revenue | NT$0 |
| Gross Profit | NT$0 |
| Other Expenses | NT$328.75m |
| Earnings | -NT$328.75m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.71 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did 6575 perform over the long term?
See historical performance and comparison